Government
High court upholds ban on early access to experimental drugs
NEWS IN BRIEF — Posted Feb. 4, 2008
The U.S. Supreme Court on Jan. 14 upheld a ruling that terminally ill patients should not be given early access to medications that have not yet gained Food and Drug Administration approval.
Justices, without comment, turned down an appeal by the Abigail Alliance for Better Access to Developmental Drugs. The patient advocacy organization was seeking a shortcut to treatments that appear effective after phase 1 testing. The alliance sued the FDA, saying the agency violated dying patients' constitutional rights by making them wait.
But the government and some physicians worried that unfettered early access would jeopardize patients' quality of life and the clinical trial process. The U.S. Court of Appeals for the District of Columbia Circuit agreed in August 2007. The Supreme Court's denial allows that ruling to stand.
The Abigail Alliance could not be reached for comment.
The FDA said it is exploring ways to expand existing compassionate-use programs.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2008/02/04/gvbf0204.htm.












